Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P23109

UPID:
AMPD1_HUMAN

ALTERNATIVE NAMES:
AMP deaminase isoform M; Myoadenylate deaminase

ALTERNATIVE UPACC:
P23109; A8K5N4; B2RAM1; F2Z3B3; Q5TF00; Q5TF02

BACKGROUND:
AMP deaminase 1, identified by its alternative names AMP deaminase isoform M and Myoadenylate deaminase, is integral to the process of energy metabolism. It facilitates the conversion of AMP to IMP, a key step in the purine nucleotide cycle that is essential for the replenishment of adenosine triphosphate (ATP) in muscle cells.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of AMP deaminase 1 could open doors to potential therapeutic strategies. Its deficiency is directly linked to a specific myopathy, characterized by exercise-induced discomfort and fatigue, underscoring the enzyme's significance in muscle function and energy homeostasis. Exploring its mechanisms could lead to novel treatments for related metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.